Table I.
A. GSK cohort | |||
---|---|---|---|
Characteristics | Phase IIB studies | Phase IIIA studies | HZA 106837 |
Total patients | 1,125 | 679 | 868 |
Age (y) | 42.1±16.8 | 44.2±15.6 | 42.7±14.7 |
Sex: %female | 61.2 | 58.6 | 68.6 |
BMI (kg/m2) | 27.9±6.7 | 27.9±5.2 | 27.6±5.9 |
Height (cm) | 167.9±13.4 | 165.9±7.8 | 163.9±8.8 |
Asthma duration (y) | 17.7±13.4 | 14.9±13.0 | 15.7±11.8 |
FEV1 at baseline (% predicted) | 69.9±10.1 | 69.2±10.4 | 71.7±11.8 |
FEV1 change (% predicted) | 7.2±13.4 | 6.9±13.0 | 6.1±11.8 |
B. GERA cohort | ||
---|---|---|
Characteristics | Asthma patients with exacerbation | Asthma patients without exacerbation |
Total patients | 3,097 | 2,613 |
Age (y) | 63.8±14.0 | 63.4±15.2 |
Sex: %female | 2168 (70.0%) | 1765 (67.5%) |
BMI (kg/m2) | 29.2±6.2) | 28.6±6.3 |
Smoking status: %ever smoker | 1378 (45.9%) | 1027 (40.9%) |
Allergic rhinitis status | 1404 (45.3%) | 1113 (42.6%) |
Gastroesophageal reflux disease | 983 (31.7%) | 651 (24.9%) |
C. GALA II study | ||
Characteristics | Asthma patients with exacerbation | Asthma patients without exacerbation |
Total patients | 567 | 287 |
Age (y) | 11.9±3.1 | 12.5±3.3 |
Sex: %female | 246 (43.4%) | 119 (41.5%) |
D. SAGE study | ||
Characteristics | Asthma patients with exacerbation | Asthma patients without exacerbation |
Total patients | 256 | 237 |
Age (y) | 13.2±3.4 | 13.8±3.4 |
Sex: %female | 123 (48.0%) | 103 (43.5%) |
E. SLOVENIA cohort | ||
Characteristics | ICS non-responders | ICS responders |
Total patients | 94 | 72 |
Age (y) | 10.7±3.2 | 11.2±3.5 |
Sex: %female | 35 (37.2%) | 33 (45.8%) |
F. UK Biobank participants | ||
Characteristics | Asthma patients | Healthy controls |
Total patients | 19,216 | 162,637 |
Age (y) | 55.8±8.4 | 57.1±8.3 |
Sex: %female | 62.2 | 55.4 |
BMI (kg/m2) | 27.9±5.0 | 27.1±4.7 |
Smoking status: %ever smoker | 57.4 | 58.1 |